1. Scrip
  2. >>New Products

Generex's oral insulin submitted for approval in Syria

 
• By John Davis

[C#200000856:Generex] Biotechnologyhas submitted a marketing application in Syria for its oral insulin product, [C#200000856:Generex] Oral-lyn, and expects approval before the end of next year. [C#200000856:Generex]'s product uses its RapidMist device to deliver a liquid spray of insulin to the lining of the mouth. The product is available in Ecuador, and has been approved for sale in India. Phase III clinical trials are under way in the US and elsewhere.

Generex Biotechnologyhas submitted a marketing application in Syria for its oral insulin product, Generex Oral-lyn, and expects approval before the end of next year. Generex's product uses its RapidMist device to deliver a liquid spray of insulin to the lining of the mouth. The product is available in Ecuador, and has been approved for sale in India. Phase III clinical trials are under way in the US and elsewhere.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from New Products

Madrigal Regains Lead With Rezdiffra MASH Approval In EU

 
• By Joseph Haas

Four days after Wegovy became the second approved MASH therapy in the US, Rezdiffra gets the first European approval. Plans are for an initial launch in Germany.

Wegovy’s Win In MASH Gives Novo A Much-Needed Edge Over Lilly

 
• By Manas Mishra

Just days after discontinuing a Phase III trial for a separate MASH compound, Novo Nordisk has secured the US FDA’s accelerated approval for Wegovy to treat the fatty liver disease.

Pipeline Watch: Seven Approvals And Five Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Tonix Ready To Revive Fibromyalgia Market With Tonyma

 
• By Joseph Haas

The first new drug for fibromyalgia since 2009, Tonyma is a reformulation of cyclobenzaprine intended for chronic therapy. Tonix said the drug targets non-restorative sleep.

More from Scrip

Celldex Bullish On Barzolvolimab Despite Study Miss

 
• By Kevin Grogan

All eyes on chronic urticaria after eosinophilic esophagitis disappointment.

BioNTech/BMS Bispecific Shows Early Promise In Small Cell Lung Cancer

 
• By Andrew McConaghie

An updated abstract from the World Conference on Lung Cancer has given analysts confidence in BioNTech’s VEGF-A/PD-L1 bispecific challenger

DMD Plans Remain Central For Regenxbio Despite Hunter Syndrome FDA Approval Delay

 
• By Manas Mishra

All eyes will be on Regenxbio's DMD data, expected next year, as the drug developer navigates a three-month delay to its FDA approval hopes for its Hunter syndrome gene therapy.